Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Chinese Journal of Natural Medicines (English Ed.) ; (6): 749-759, 2020.
Article in English | WPRIM | ID: wpr-827780

ABSTRACT

This study aimed to investigate the effects of Sargassum fusiforme polysaccharide (SFPS I, II, and III) on the apoptosis and regulation of human erythroleukemia (HEL) cells. The effect of different doses of SFPS on HEL cell growth was detected using the Cell Counting Kit-8 method, and apoptosis was detected by Hoechst staining. Cell cycle distribution and apoptosis were detected using flow cytometry. Expression of the cell cycle gene, p53, antiapoptotic genes, Bcl-xL and Bcl-2, and pro-apoptotic genes, Bax, Bad, and Caspase-3, as well as the expression of the corresponding proteins, were detected using real-time quantitative polymerase chain reaction (qPCR) and Western blot. The results showed that SFPS II and III decreased HEL cell viability and induced HEL cell apoptosis. Different concentrations of SFPS (I, II, and III) were detected that induced much less toxic effect in normal human embryonic lung (MRC-5) cells, and SFPS I increased cell proliferation, indicating its favorable selectivity towards cancer cells. The mechanism by which SFPS induced apoptosis was also found to be related to the induction of cell cycle arrest in the G/G phase and the increased expression of apoptosis-related genes and proteins. We concluded that SFPS induces HEL cell apoptosis, possibly via activation of the Caspase pathway, providing the theoretical basis for the development of SFPS-based anti-tumor drug products.

2.
Journal of Experimental Hematology ; (6): 110-114, 2019.
Article in Chinese | WPRIM | ID: wpr-774350

ABSTRACT

OBJECTIVE@#To evaluate the prognostic value of R-ISS staging system in patients with newly diagnosed multiple myeloma (NDMM).@*METHODS@#The Chinical data of 412 patients with NDMM in our hospital from May 2010 to May 2016 were retrospectively analyzed. All the patients received conventional chemotherapy or thalidomide or bortezomib-based chemotherapy. All the patients with NDMM were divided into R-ISS-Ⅰ, R-ISS-Ⅱ and R-ISS-Ⅲ groups according to R-ISS staging system on the basis of ISS staging system, cytogenetics and LDH level. The progression-free survival (PFS) time and overall survival(OS) of different groups were compared.@*RESULTS@#Among all 412 patients, 76 were rated as R-ISS-Ⅰ, 259 as R-ISS-Ⅱ and 77 as R-ISS-Ⅲ. The median PFS time in 3 groups were 44, 25 and 14 months respectively (P<0.01). The median OS time of the 3 groups were not reached 54 and 25 months respectively (P<0.01). Further analysis also found that statistically different survival associated with different R-ISS groups in the conventional chemotherapy group (P<0.05), bortezomib-based chemotherapy group (P<0.01), thalidomide-based chemotherapy group (P<0.01), transplantation group (P<0.05), different-age stratified group (≤65y P<0.01, 66-75y P<0.01,≥76y P<0.01), damaged renal function group (P<0.01) and extramedullary infiltration group (P<0.01).@*CONCLUSION@#PFS and OS in the patients with multiple myeloma were different among three distrinct R-ISS stages. The R-ISS staging system has important clinical significance for the prognosis evaluation of multiple myeloma.


Subject(s)
Humans , Antineoplastic Combined Chemotherapy Protocols , Bortezomib , Multiple Myeloma , Diagnosis , Neoplasm Staging , Prognosis , Retrospective Studies , Thalidomide , Treatment Outcome
3.
Journal of Experimental Hematology ; (6): 1403-1406, 2018.
Article in Chinese | WPRIM | ID: wpr-689923

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the prognostic value of karyotypic abnormalities in evaluation of prognosis of patients with multiple myeloma.</p><p><b>METHODS</b>The clinical and laboratory data of patients with newly diagnosed multiple myeloma (NDMM) were retrospectively analyzed in our hospital from May 2010 to May 2016. Patients who carried t(4; 14), t(14; 16) or 17P (at least one of them) were defined as the patients with high-risk karyotype, whereas patients characterized by the absence of the above-mentioned abnormalities were defined as patients with standard-risk karyotype. PFS (progression-free survival, PFS) and OS (over all survival, OS) time was compared between the 2 groups.</p><p><b>RESULTS</b>There were 110 cases in the high-risk group, and 302 cases in the standard-risk group. The clinical characteristics, such as age, sex, ISS stage and treatment regimen etc were not statistically different between 2 groups. The median OS time of patients in the high-risk and standard-risk groups were 42 months (CI 95%: 34.375-49.625 months) and 53 months (CI 95%: 46.310-59.690 months) (P<0.05). The median PFS time of patients in the high-risk group and standard-risk groups was 21 months (CI95%: 17.198-24.802 months) and 27 months (CI95%: 23.406-30.594 months) (P<0.05).</p><p><b>CONCLUSION</b>Among patients with newly diagnosed MM, the PFS and OS time in the patients with high-risk karyotype is shorter than that in patients with standard-risk karyotyp.</p>

4.
Journal of Experimental Hematology ; (6): 1470-1475, 2016.
Article in Chinese | WPRIM | ID: wpr-332667

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the effect of metronomic chemotherapy of low dose phosphoramide combined with prednisolone (CP metronomic chemotherapy) on proliferation and apoptosis of RPMI 8226 cells, and to explore its regulating effect on Notch1/NF-κB signaling pathways.</p><p><b>METHODS</b>Experiment was divided into the DMSO control group, and the phosphoramide mustard (PM) group, the prednisolone group, the phosphoramide mustard plus prednisolone group (the CP group). RPMI 8226 cells were treated with different drugs, CCK-8 method was used to detect cell proliferation, flow cytometry was used to detect the cell cycle and apoptosis, reverse transcription PCR was used to detect Notch1 and NF-κB mRNA expression level.</p><p><b>RESULTS</b>Compared with DMSO control group, RPMI8226 cell proliferation inhibition rate in all the PM, prednisolone and CP groups increased significantly with prolonging of time (r of 0.994,0.996,0.999, respectively, P<0.001). And at the same time, the inhibitory rate of cell proliferation was significantly different; the cell inhibitory rate in PM group was lowest, that in CP group was highgest, that in prednissone group was intermediate (P<0.01). After 48 hours, compared with the DMSO control group, the G/Gcell proportion in treatment group increased significantly, S phase cell proportion decreased significantly, especially in PM and CP groups. The G/M phase cell proportion increased in PM group, while reduced in the prednisolone and the CP groups. After 48 hours, compared with the DMSO control group, RPMI 8226 cell apoptosis rate increased as follow: in PM, pre-dnisolone and CP group(P<0.01). After 48 hours, compared with the DMSO control group, Notch1 and NF-κB mRNA expression in the prednisolone, the PM and the CP group decreased significantly(P<0.001).</p><p><b>CONCLUSION</b>CP metronomic chemotherapy can significantly reduce RPMI 8226 cell proliferation, promote RPMI 8226 cell apoptosis, arrest RPMI 8226 cells mainly in the G/Gphase, and significantly reduce Notch1 and NF-κB expression levels. It is suggested that Notch1/NF-κB signaling pathways is involved in CP metronomic chemotherapy for MM.</p>

5.
Journal of Experimental Hematology ; (6): 241-244, 2014.
Article in Chinese | WPRIM | ID: wpr-349728

ABSTRACT

Myeloid differentiation factor (MyD88) is an important adaptor protein mediating the signal transduction of most Toll-like receptors (TLR), interleukin-1 receptor (IL-1R) and interleukin-18 receptor (IL-18R) that play a key role to mediate innate immune response. Recently, activating of MYD88 L265 mutation has been reported in about of 90% lymphoplasmacytoid lymphoma/Waldenström's Macroglobulinemia, about of 29% activated type diffuse large B-cell lymphoma and other subtypes of B cell tumors demonstrating the MyD88 signaling plays an important role in B cell tumorigenesis, and inhibitors targeting MyD88 might become a new remedy for B cell tumors. In this review, the latest advances in the roles of MyD88 L265P mutation in B cell tumorigenesis were summarized.


Subject(s)
Humans , Carcinogenesis , Lymphoma, Large B-Cell, Diffuse , Mutation , Myeloid Differentiation Factor 88 , Genetics , Signal Transduction
6.
Acta Pharmaceutica Sinica ; (12): 1400-1405, 2014.
Article in Chinese | WPRIM | ID: wpr-299121

ABSTRACT

The effect of astaxanthin on N(Ω)-nitro-L-arginine methyl ester (L-NAME) induced preeclampsia disease rats was investigated. Thirty pregnant Sprague-Dawley rats were randomly divided into three groups (n = 10): blank group, L-NAME group and astaxanthin group. From day 5 to 20, astaxanthin group rats were treated with astaxanthin (25 mg x kg(-1) x d(-1) x bw(-1)) from pregnancy (day 5). To establish the preeclamptic rat model, L-NAME group and astaxanthin group rats were injected with L-NAME (125 mg x kg(-1) x d(-1) x bw(-1)) from days 10-20 of pregnancy. The blood pressure and urine protein were recorded. Serum of each group was collected and malondialdehyde (MDA), superoxide dismutase (SOD) and nitric oxide synthase (NOS) activities were analyzed. Pathological changes were observed with HE stain. The expression of NF-κB (nuclear factor kappa B), ROCK II (Rho-associated protein kinase II), HO-1 (heme oxygenase-1) and Caspase 3 were analyzed with immunohistochemistry. L-NAME induced typical preeclampsia symptoms, such as the increased blood pressure, urinary protein, the content of MDA, etc. Astaxanthin significantly reduced the blood pressure (P < 0.01), the content of MDA (P < 0.05), and increased the activity of SOD (P < 0.05) of preeclampsia rats. The urinary protein, NO, and NOS were also decreased. HE stain revealed that after treated with astaxanthin, the thickness of basilal membrane was improved and the content of trophoblast cells and spiral arteries was reduced. Immunohistochemistry results revealed that the expressions of NF-κB, ROCK II and Caspase 3 in placenta tissue were effectively decreased, and HO-1 was increased. Results indicated that astaxanthin can improve the preeclampsia symptoms by effectively reducing the oxidative stress and inflammatory damages of preeclampsia. It revealed that astaxanthin may be benefit for prevention and treatment of preeclampsia disease.


Subject(s)
Animals , Female , Pregnancy , Rats , Blood Pressure , Caspase 3 , Metabolism , Disease Models, Animal , Heme Oxygenase (Decyclizing) , Metabolism , Malondialdehyde , Metabolism , NF-kappa B , Metabolism , NG-Nitroarginine Methyl Ester , Nitric Oxide Synthase , Metabolism , Oxidative Stress , Placenta , Pre-Eclampsia , Drug Therapy , Rats, Sprague-Dawley , Superoxide Dismutase , Metabolism , Xanthophylls , Therapeutic Uses , rho-Associated Kinases , Metabolism
7.
Acta Pharmaceutica Sinica ; (12): 280-284, 2011.
Article in Chinese | WPRIM | ID: wpr-348964

ABSTRACT

This study is designed to investigate the anti-tumor and anti-angiogenesis mechanism of carrageenan oligosaccharides. The effects of carrageenan oligosaccharides on basic fibroblast growth factor (bFGF) induced cell proliferation, heparanase activity and bFGF binding ability were evaluated in human cervical cancer cells (HeLa) and human umbilical vein endothelial cells (HUVEC). Results indicate that, at rational concentrations, carrageenan oligosaccharides showed low cytotoxic effect. At relatively low concentrations (0.2-200 microg x mL(-1)), these oligosaccharides could competitively bind bFGF and inhibit bFGF induced cell proliferation. In these samples, oligo-lambda-carrageenans (dp2-8) were the most potent bFGF antagonists. At concentration of 20 microg x mL(-1), their inhibitory ratio reached to 30%. The heparanase enzyme assay revealed that three kinds of carrageenan oligosaccharides showed different inhibitory activities to two cell lines. For HeLa cell, oligo-lambda-carrageenans showed highest inhibitory effect, but for HUVEC, oligo-kappa-carrageenans (dp9-17) were the best inhibitors. Current observations demonstrated that the biological activities of carrageenan oligosaccharides are closely related to the molecular weight, carbohydrate structure and the content and linking position of sulfur groups. Carrageenan oligosaccharides with high sulfate fraction, 2-8 units saccharide size and suitable molecular structure are able to achieve potent heparin sulfate-like compounds.


Subject(s)
Humans , Angiogenesis Inhibitors , Pharmacology , Antineoplastic Agents , Pharmacology , Carrageenan , Pharmacology , Cell Proliferation , Fibroblast Growth Factor 2 , Metabolism , Glucuronidase , Metabolism , HeLa Cells , Human Umbilical Vein Endothelial Cells , Oligosaccharides , Pharmacology , Protein Binding
8.
Acta Pharmaceutica Sinica ; (12): 521-526, 2011.
Article in Chinese | WPRIM | ID: wpr-348925

ABSTRACT

This study is to investigate the protective effect of astaxanthin against injured hepatocyte L-02 cells induced by sodium azide (NaN3) and reveal the possible mechanisms. Hepatocyte L-02 cells were exposed to 100 mmol.L-1 NaN3 with various concentrations of astaxanthin pre-incubated, then the cell viability was measured by MTT method; The level of reactive oxygen species (ROS) was determined by DCFH-DA method; The changes of mitochondrial membrane potential (MMP) and apoptosis ratio were detected by JC-1 method and Annexin V-FITC/PI double stain method, respectively. Results showed that after cells were exposed to 100 mmol.L-1 NaN3 for 3 hours, the cell viability significantly decreased; ROS level and the percentage of late phase apoptosis increased obviously; MMP was also declined. When cells were pretreated with astaxanthin, the cell damage and late phase apoptosis ratio reduced and MMP was maintained. However, the level of ROS showed insignificant decrease (P>0.05). The beneficial concentration of astaxanthin in improving cell viability and MMP was not in a dose dependent manner and the most effective of which was 0.10 nmol.L-1 (P<0.01). In order to reveal its possible non-antioxidant mechanism, mitochondrial membrane was imitated and H+ transferring function of astaxanthin was also detected by bilayer lipid membrane (BLM) method. Results showed that 2.0% astaxanthin could transfer H+ efficiently. These suggested the mechanisms of astaxanthin in protection of hepatocyte L-02 cells not via its ROS quenching capability but via its H+ transferring function, which improved the mitochondrial function and had the sequence biology effects.


Subject(s)
Humans , Antioxidants , Pharmacology , Apoptosis , Cell Line , Cell Survival , Hepatocytes , Cell Biology , Hydrogen-Ion Concentration , Membrane Potential, Mitochondrial , Protons , Reactive Oxygen Species , Metabolism , Sodium Azide , Toxicity , Xanthophylls , Pharmacology
9.
Journal of Experimental Hematology ; (6): 1138-1142, 2010.
Article in Chinese | WPRIM | ID: wpr-237578

ABSTRACT

This study was aimed to investigate the clinical feasibility of using multiplex PT-PCR assay for screening rare/cryptic chromosome translocations in patients with de novo acute myeloid leukemia. For 126 patients with de novo AML-M4/M5 without common chromosome translocations including t(15;17), t(8;21) and t(16;16), 3 parallel multiplex RT-PCR assays were set up to detect 6 mll-related gene rearrangements (mll/af10, mll/af17, mll/ell, mll/af9, mll/af6 and mll/enl) with low detection rate and 4 rare fusion genes (dek/can, tls/erg, aml1/mds (evi1) and npm/mlf1). The results showed that 11 patients with positive result from 126 patients were detected which involved in 5 molecular abnormalities. Among them, 10 cases were AML-M5 (16.67%), 1 cases AML-M4 (1.51%). The marker chromosomes were observed in 2 cases out of 11 cases through conventional karyotyping analysis, the karyotyping analysis in 1 case was not performed because this case had 1 mitotic figure only, no any cytogenetic aberrations were found in other 8 cases through R-band karyotyping analysis. It is concluded that multiplex RT-PCR designed in this study can quickly, effectively and accurately identify the rare/cryptic chromosome translocations and can be used in clinical detection.


Subject(s)
Humans , Chromosome Banding , Gene Rearrangement , Genetic Testing , Leukemia, Myeloid, Acute , Genetics , Reverse Transcriptase Polymerase Chain Reaction , Methods , Translocation, Genetic
10.
Acta Pharmaceutica Sinica ; (12): 980-986, 2009.
Article in Chinese | WPRIM | ID: wpr-354608

ABSTRACT

This study is to investigate the effect of fascaplysin on human cervical cancer cells (HeLa) in order to provide insights into the mechanisms of growth suppression involved in fascaplysin-mediated apoptosis. Cytotoxic activity of fascaplysin on HeLa cells was determined using MTT assay, cell cycle analysis, and apoptosis (Annexin V-FITC and PI double staining) studies. The role of the molecules in cell cycle regulation and apoptosis was analyzed by Western blotting and flow cytometry. Fascaplysin markedly inhibited HeLa cells proliferation in a dose-dependent manner, however, did not provoke G1 phase arrest in HeLa cells with downregulation of CDK4, cyclin D1 and CDK4-specific Ser795 pRb phosphorylation. Furthermore, fascaplysin induced significantly apoptosis evidenced by sub-G1 peak and Annexin V-FITC and PI double staining. The molecular mechanism of fascaplysin-induced apoptosis was characterized with the activation of caspase-3, -8, and -9, truncation of Bid, release of cytochrome c into cytosol, and down-regulation of Bcl-2 level. Fascaplysin exhibits anti-proliferation effect towards human cervical cancer HeLa cells through induction of apoptosis via extrinsic death pathway and mitochondrial pathway, but not arresting cell cycle progression at G1 phase. All together, these data sustain our contention that fascaplysin has anticancer properties and merits further investigation as a potential therapeutic agent.


Subject(s)
Humans , Apoptosis , Cell Cycle Checkpoints , Cell Proliferation , HeLa Cells , Indoles , Pharmacology , Mitochondria , Metabolism
11.
Acta Pharmaceutica Sinica ; (12): 474-479, 2008.
Article in Chinese | WPRIM | ID: wpr-277828

ABSTRACT

To study the anti-proliferation effect of lambda-carrageenan oligosaccharides (lambda-CO) on human umbilical vein endothelial cells (HUVECs) and expression of apoptotic relevant genes, the influence of lambda-CO on HUVECs proliferation was measured by MTT assay; apoptotic rate, cell cycle distribution and the level of active caspase-3 of HUVECs were analyzed using flow cytometry; the mRNA level of apoptosis related genes was determined by RT-PCR. At a high concentration of 1 mg x mL(-1), lambda-CO significantly inhibited the endothelial cell proliferation. Annexin-V FITC/PI double stain assay showed that when treated with 0, 0.8, 1 mg x mL(-1) of lambda-CO for 24 h, cell apoptotic rates were (1.67 +/- 1.6)%, (11.48 +/- 2.4)% and (13.81 +/- 2.2)%, respectively, when treated for 48 h, cell apoptotic rates were (2.02 +/- 2.3)%, (13.84 +/- 1.9)% and (38.72 +/- 2.5)%, respectively, cell cycle assay showed the decrease of cells in G0/G1 phase, and increase in S phase. Furthermore, we observed the level of active caspase-3 increased in a dose-dependent manner at 24 th and 48 th. RT-PCR results indicated that mRNA of TNFalpha, p53, caspase-8 and caspase-3 in cells increased after treated with lambda-CO. lambda-CO induce apoptosis of HUVECs in a dose-dependent way and arrests cells at S phase, which mainly due to the up-regulation of apoptotic genes such as TNFalpha, p53, caspase-8, caspase-3 and increase the level of active caspase-3.


Subject(s)
Humans , Angiogenesis Inhibitors , Pharmacology , Apoptosis , Carrageenan , Pharmacology , Caspase 3 , Genetics , Metabolism , Caspase 8 , Genetics , Cell Cycle , Cell Proliferation , Cells, Cultured , Endothelial Cells , Cell Biology , Oligosaccharides , Pharmacology , RNA, Messenger , Metabolism , Tumor Necrosis Factor-alpha , Genetics , Tumor Suppressor Protein p53 , Genetics , Umbilical Veins , Cell Biology
12.
Acta Pharmaceutica Sinica ; (12): 595-600, 2007.
Article in Chinese | WPRIM | ID: wpr-281870

ABSTRACT

This study was designed to evaluate the inhibition effect of lambda-carrageenan oligosaccharides on neovascularization in vitro by chick chorioallantoic membrane (CAM) model and human umbilical vein endothelial cell ( HUVEC). lambda-Carrageenan oligosaccharides caused a dose-dependent decrease of the vascular density of CAM, and adversely affected capillary plexus formation. At a high concentration of 1 mg x mL(-1), this compound inhibited the endothelial cell proliferation, while low concentration of lambda-carrageenan oligosaccharides (< 250 microg x mL(-1)) affected the cell survival slightly (> 95%). Different cytotoxic sensitivity of lambda-carrageenan oligosaccharides in three kinds of cells was observed, of which HUVEC is the most sensitive to this oligosaccharides. The inhibitory action of lambda-carrageenan oligosaccharides on the endothelial cell invasion and migration was also observed at relatively low concentration (150 - 300 microg x mL(-1)) through down-regulation of intracellular matrix metalloproteinases-2 (MMP-2) expression on endothelial cells. Current observations demonstrated that lambda-carrageenan oligosaccharides are potential angiogenesis inhibitor with combined effects of inhibiting invasion, migration and proliferation.


Subject(s)
Animals , Chick Embryo , Humans , Angiogenesis Inhibitors , Pharmacology , Carrageenan , Pharmacology , Cell Movement , Cell Proliferation , Chorioallantoic Membrane , Cell Biology , Endothelial Cells , Matrix Metalloproteinase 2 , Oligosaccharides , Pharmacology
13.
Acta Pharmaceutica Sinica ; (12): 903-907, 2005.
Article in Chinese | WPRIM | ID: wpr-253544

ABSTRACT

<p><b>AIM</b>To evaluate the hepatocyte protective effect of agarohexaose against indirect oxidative stress injury induced by antimycin A.</p><p><b>METHODS</b>Antimycin A was used to induce oxidative injury of human hepatocyte L-02. The oxidative degree in cells was detected by dichlorofluorescin diacetate (DCFH-DA) and the fluorescence generation was recorded by flow cytometer and fluorescent microscope. The apoptosis of L-02 cells induced by oxidation was identified by TUNEL test, and the morphologic features of cells were also observed.</p><p><b>RESULTS</b>Agarohexaose at concentration of 1 mg x mL(-1) inhibited the oxidation of DCFH into DCF significantly. The fluorescence intensity and oxidized cell number decreased after the incubation with agarohexaose. The photomicrographs of antimycin A and agarohexaose treated cells revealed that agarohexaose could reduce the apoptotic morphologic features. The TUNEL results also indicated that the number of apoptotic cells decreased significantly after the treatment of agarohexaose.</p><p><b>CONCLUSION</b>Agarohexaose could inhibit the sudden increase reactive oxygen species (ROS) in cells significantly, and it also protected cells against oxidative stress injury in vitro.</p>


Subject(s)
Humans , Antimycin A , Pharmacology , Antioxidants , Pharmacology , Apoptosis , Cells, Cultured , DNA Breaks , Hepatocytes , Cell Biology , Metabolism , Oligosaccharides , Chemistry , Pharmacology , Oxidative Stress , Reactive Oxygen Species , Metabolism
SELECTION OF CITATIONS
SEARCH DETAIL